ライフサイエンスコーパス: antiretroviral therapy

1 s weight gain with integrase inhibitor-based antiretroviral therapy.

2 These pathologies persist despite antiretroviral therapy.

3 on facilitates immune escape and complicates antiretroviral therapy.

4 and rilpivirine dosed every 4 weeks to oral antiretroviral therapy.

5 igational principal component of long-acting antiretroviral therapy.

6 unt <= 100 cells/mul, and 35% were receiving antiretroviral therapy.

7 HIV) co-infected patients receiving combined antiretroviral therapy.

8 outh Africa, to define a cohort of PWLHIV on antiretroviral therapy.

9 ntributes to viral rebound upon cessation of antiretroviral therapy.

10 discontinuing CPT in stabilized patients on antiretroviral therapy.

11 over drug-drug interactions associated with antiretroviral therapy.

12 as darunavir (DRV), are the key component of antiretroviral therapy.

13 , 11.1) years and 97.4% received combination antiretroviral therapy.

14 7 cells/muL, 64% were women, and 38% were on antiretroviral therapy.

15 inority variants, can compromise response to antiretroviral therapy.

16 living with HIV (PLWH) receiving combination antiretroviral therapy.

17 achieve virologic control in the absence of antiretroviral therapy.

18 teristics of viral control in the absence of antiretroviral therapy.

19 eplication-competent viral reservoirs during antiretroviral therapy.

20 immunodeficiency virus-infected patients on antiretroviral therapy.

21 nfection and 112/122 (91.8%) had a record of antiretroviral therapy.

22 high proportions of HIV virologic control on antiretroviral therapy.

23 ving with HIV who were receiving suppressive antiretroviral therapy.

24 Viral replication can be blocked by antiretroviral therapy.

25 (+) T cell loss after the discontinuation of antiretroviral therapy.

26 onprogressors that does not require combined antiretroviral therapy.

27 ut of people with HIV-1, even with effective antiretroviral therapy.

28 as safe and effective as optimally delivered antiretroviral therapy.

29 t solid organ transplant (SOT) recipients on antiretroviral therapy.

30 , cirrhosis, body mass index, and/or type of antiretroviral therapy.

31 -4 in HBV/HIV co-infected adults on combined antiretroviral therapy.

32 the treatment of HIV as part of combination antiretroviral therapy.

33 in 586 women who were naive to highly active antiretroviral therapy.

34 We also discuss the role of rituximab and antiretroviral therapy.

35 s with HCV-1/HIV coinfection suppressed with antiretroviral therapy.

36 matory syndrome (TB-IRIS) when they commence antiretroviral therapy.

37 achieving viral remission in the absence of antiretroviral therapy.

38 are living with HIV-1 worldwide, and despite antiretroviral therapy, 30 to 50% of the people living w

39 .7%); HIV-infected adults 18-40-years-old on antiretroviral therapy (41.4% reduction from 15.2% to 8.

40 h HIV face challenges to their wellbeing and antiretroviral therapy adherence and have poor treatment

41 0.007) that is not explained by differential antiretroviral therapy adherence.

42 We observed a faster HIV DNA decay during antiretroviral therapy among cannabis users, compared to

43 HIV-1) infection who have undergone multiple antiretroviral therapies and have limited options for tr

44 HF, there were 434 PHIV; 90% were prescribed antiretroviral therapy and 62% were virally suppressed.

45 The risk of drug-drug interactions between antiretroviral therapy and aramchol, cenicriviroc, elafi

46 CD4 count was lower both at initiation of antiretroviral therapy and at VF in participants who wen

47 iving with perinatally-acquired HIV, despite antiretroviral therapy and CD4 preservation/reconstituti

48 SM has not been examined since the advent of antiretroviral therapy and molecular diagnostics.

49 to avoid the potential pitfalls of lifelong antiretroviral therapy and other HIV-related disorders,

50 ivate provirus expression in the presence of antiretroviral therapy and target virus-expressing cells

51 All patients were on antiretroviral therapy and virologically suppressed at t

52 uman immunodeficiency virus (even when under antiretroviral therapy), and hepatitis C virus or those

53 chiatric Interview depression module, taking antiretroviral therapy, and antidepressant-naive.

54 ntral nervous system, imperfect adherence to antiretroviral therapy, and depression.

55 load, study type, previous time on combined antiretroviral therapy, and follow-up interval during TI

56 dritic cells (FDCs), persists in vivo during antiretroviral therapy, and likely contributes to viral

57 their CD4 + T cell pool after initiation of antiretroviral therapy, and their prognosis is inferior

58 8 with longstanding HIV infection, 88% under antiretroviral therapy; and 57 women without HIV from th

59 cell counts (nadir, <200/muL; >350/muL after antiretroviral therapy), antigen-specific CD4+ T-cell me

60 People living with HIV on effective antiretroviral therapy are at increased risk of cardiova

61 [OR], 3.7; P < .001), imperfect adherence to antiretroviral therapy (ART) (OR, 2.8; P < .001), and de

62 ople living with HIV, initiate and retain on antiretroviral therapy (ART) 90% of those diagnosed, and

63 AD) events have been associated with certain antiretroviral therapy (ART) agents.

64 reatment, but the extent to which the use of antiretroviral therapy (ART) and anti-tuberculosis medic

65 n immunodeficiency virus (HIV) infection and antiretroviral therapy (ART) are associated with bone lo

66 Latent HIV-1 persists indefinitely during antiretroviral therapy (ART) as an integrated silent gen

67 a instead of efavirenz for people initiating antiretroviral therapy (ART) because of superior tolerab

68 Although antiretroviral therapy (ART) can control the virus, it d

69 Immune restoration on antiretroviral therapy (ART) can drive inflammation in p

70 Antiretroviral therapy (ART) cannot cure HIV infection b

71 Antiretroviral therapy (ART) cannot eradicate human immu

72 imitations include lack of data on access to antiretroviral therapy (ART) care and social or clinical

73 contraceptive efficacy and interaction with antiretroviral therapy (ART) complicate counseling.

74 Human immunodeficiency virus (HIV) and antiretroviral therapy (ART) confer cardiovascular disea

75 Antiretroviral therapy (ART) coverage was 80.2% among th

76 Viral rebound following antiretroviral therapy (ART) discontinuation in HIV-1-in

77 A 6-month interruption of supply of antiretroviral therapy (ART) drugs across 50% of the pop

78 Understanding the impact of antiretroviral therapy (ART) duration on HIV-infected ce

79 In adults starting antiretroviral therapy (ART) during acute infection, 2%

80 with usual care (UC), offering same-day (SD) antiretroviral therapy (ART) during home-based human imm

81 collected from 12 persons with HIV who began antiretroviral therapy (ART) during very early HIV infec

82 lock-and-lock HIV cure approaches.IMPORTANCE Antiretroviral therapy (ART) effectively reduces an indi

83 ty of HIV infection and prevails in the post-antiretroviral therapy (ART) era.

84 d regimens are now recommended as first-line antiretroviral therapy (ART) for adults with human immun

85 ion (WHO) recommends immediate initiation of antiretroviral therapy (ART) for all HIV-positive patien

86 A key component of antiretroviral therapy (ART) for HIV patients is the nuc

87 ed 150 DBS specimens from ongoing studies of antiretroviral therapy (ART) for HIV-2 infection in Sene

88 Antiretroviral therapy (ART) generally reduces plasma HI

89 The use of antiretroviral therapy (ART) has remarkably decreased th

90 While the advent of combination antiretroviral therapy (ART) has significantly improved

91 counts despite fully suppressed HIV-1 RNA on antiretroviral therapy (ART) have been associated with i

92 Advances in antiretroviral therapy (ART) have made it possible for p

93 VID-19) among HIV-positive persons receiving antiretroviral therapy (ART) have not been characterized

94 ns affected viral rebound after cessation of antiretroviral therapy (ART) in 18 acutely treated and d

95 lected data on HIV-positive adults receiving antiretroviral therapy (ART) in Cape Town, South Africa

96 Initiation of antiretroviral therapy (ART) in early compared with chro

97 Despite the use of antiretroviral therapy (ART) in HIV-1 infected mothers a

98 ned among individuals on failing second-line antiretroviral therapy (ART) in low- and middle-income c

99 persist in people living with HIV (PLWH) on antiretroviral therapy (ART) in multiple CD4(+) T cell s

100 Late initiation of HIV antiretroviral therapy (ART) in pregnancy is associated

101 for HIV-positive children and adolescents on antiretroviral therapy (ART) in sub-Saharan Africa.

102 th human immunodeficiency virus (HIV) taking antiretroviral therapy (ART) in sub-Saharan Africa.

103 f 150 cells per muL or less, who had not had antiretroviral therapy (ART) in the past 6 months or tub

104 Early initiation of antiretroviral therapy (ART) in vertically HIV-infected

105 ) coinfected adults starting tenofovir-based antiretroviral therapy (ART) in Zambia, median baseline

106 A prospective study of DR-TB HIV patients on antiretroviral therapy (ART) initiating bedaquiline-cont

107 Y); screen acceptance (80%), linkage-to-care/antiretroviral therapy (ART) initiation (76%), HIV trans

108 tudied the impact of clinic-level factors on antiretroviral therapy (ART) initiation and viral suppre

109 Elevated viral load (VL) early after antiretroviral therapy (ART) initiation appears frequent

110 munodeficiency virus (HIV) seroconversion to antiretroviral therapy (ART) initiation during an era of

111 ver injury challenges coinfected patients on antiretroviral therapy (ART) initiation during antituber

112 a previously described effect of very early antiretroviral therapy (ART) initiation on the rate of r

113 Late presentation to care and antiretroviral therapy (ART) initiation with advanced hu

114 or pretreatment drug resistance (PDR) before antiretroviral therapy (ART) initiation, there is little

115 on inflammatory syndrome (IRIS) and death at antiretroviral therapy (ART) initiation.

116 duals living with HIV/TB up to 48 weeks post-antiretroviral therapy (ART) initiation.

117 rsists in most HIV-1-positive individuals on antiretroviral therapy (ART) is an important milestone f

118 iremia that is not suppressed by combination antiretroviral therapy (ART) is generally attributed to

119 Combination antiretroviral therapy (ART) is highly effective in cont

120 ed mortality between men and women receiving antiretroviral therapy (ART) is incompletely characteriz

121 ular reservoirs that can reignite viremia if antiretroviral therapy (ART) is interrupted.

122 rase strand-transfer inhibitor (INSTI)-based antiretroviral therapy (ART) is recommended for human im

123 ta in HIV-1 patients with short or long-term antiretroviral therapy (ART) is unclear.

124 and might support adherence to the sustained antiretroviral therapy (ART) necessary for viral suppres

125 Initiation of antiretroviral therapy (ART) often leads to weight gain.

126 We assessed the effect of antiretroviral therapy (ART) on HIV suppression, immune

127 The effect of antiretroviral therapy (ART) on the natural history of a

128 finitely in individuals with HIV who receive antiretroviral therapy (ART) owing to a reservoir of lat

129 g with human immunodeficiency virus (PWH) on antiretroviral therapy (ART) present with an abnormal in

130 nfected with HIV-1 who initiated suppressive antiretroviral therapy (ART) regimens in infancy, HIV-1-

131 go and included participants receiving older antiretroviral therapy (ART) regimens with infrequent vi

132 mine patient characteristics associated with antiretroviral therapy (ART) reinitiation in Medicaid en

133 The number of people on antiretroviral therapy (ART) requiring treatment monitor

134 Antiretroviral therapy (ART) restores CD4+ counts and ma

135 Discontinued antiretroviral therapy (ART) results in uncontrolled HIV

136 Antiretroviral therapy (ART) scale-up in sub-Saharan Afr

137 odeficiency virus (PLWH) switched from older antiretroviral therapy (ART) to newer integrase strand t

138 Antiretroviral therapy (ART) to treat and pre-exposure p

139 The rapid scale-up of antiretroviral therapy (ART) towards the UNAIDS 90-90-90

140 Patterns of antiretroviral therapy (ART) use and immunologic correla

141 cilities, including outreach nurses, and (2) antiretroviral therapy (ART) via community pharmacies.

142 n receiving preconception dolutegravir (DTG) antiretroviral therapy (ART) vs 14 of 11 300 (0.12%) rec

143 Antiretroviral therapy (ART) was associated with signifi

144 ency virus SHIV.C.CH505.375H.dCT, and triple antiretroviral therapy (ART) was initiated after 16 week

145 ed treatment and care outcomes for adults on antiretroviral therapy (ART) when compared with standard

146 virus (HIV), many HIV-infected adults begin antiretroviral therapy (ART) when they are already sever

147 (VS) among clinically well people initiating antiretroviral therapy (ART) with high pre-ART CD4 cell

148 men who have sex with men (MSM) who started antiretroviral therapy (ART) within 1 year of their esti

149 Most patients (94.3%) were on antiretroviral therapy (ART), 88.7% had HIV virologic su

150 ons, including enhanced HIV testing, earlier antiretroviral therapy (ART), and strengthened male circ

151 se who know their HIV-positive status are on antiretroviral therapy (ART), and that 90% of those on t

152 lient retention in HIV care, prescription of antiretroviral therapy (ART), and viral suppression.

153 y countries encourage same-day initiation of antiretroviral therapy (ART), but evidence on eligibilit

154 We evaluated the association of antiretroviral therapy (ART), CD4+ count and human immun

155 Despite the global scale-up of antiretroviral therapy (ART), incarcerated people have n

156 Despite antiretroviral therapy (ART), low-level persistent HIV r

157 Prior to the widespread availability of antiretroviral therapy (ART), Men living with HIV with u

158 n of long-lived resting CD4 T cells, despite antiretroviral therapy (ART), remains a barrier to HIV c

159 After scale-up of antiretroviral therapy (ART), routine annual viral load

160 Due to the advent and success of antiretroviral therapy (ART), the number of people livin

161 based regimens now recommended as first-line antiretroviral therapy (ART), the of baseline genotypes

162 Even with treatment of HIV with antiretroviral therapy (ART), the risk of tuberculosis (

163 We analyzed antiretroviral therapy (ART)-eligible adults newly linki

164 We characterized HIVDR among antiretroviral therapy (ART)-naive and experienced parti

165 done for paired blood and semen samples from antiretroviral therapy (ART)-naive men living in Malawi

166 Detection of residual plasma viremia in antiretroviral therapy (ART)-suppressed HIV-infected ind

167 lood and rectum of HIV-negative (HIV(-)) and antiretroviral therapy (ART)-suppressed HIV-positive (HI

168 y due to the low level of antigen present in antiretroviral therapy (ART)-suppressed patients in cont

169 nodeficiency virus (SIV)-infected, long-term antiretroviral therapy (ART)-treated rhesus macaques, we

170 nd persistent induction of plasma viremia in antiretroviral therapy (ART)-treated simian immunodefici

171 ng cancers, and pulmonary infections despite antiretroviral therapy (ART).

172 ngitudinal samples from eight individuals on antiretroviral therapy (ART).

173 eatens the success of the global scale-up of antiretroviral therapy (ART).

174 iferation but are poorly studied in women on antiretroviral therapy (ART).

175 IV infection and persisted despite long-term antiretroviral therapy (ART).

176 munodeficiency virus (HIV) controllers start antiretroviral therapy (ART).

177 an persist despite decades of treatment with antiretroviral therapy (ART).

178 ammation, and clinical changes upon stopping antiretroviral therapy (ART).

179 lmonary tuberculosis among adults initiating antiretroviral therapy (ART).

180 osis (TB) or death despite the initiation of antiretroviral therapy (ART).

181 s include identifying donors and maintaining antiretroviral therapy (ART).

182 ce a lifelong cumulative exposure to HIV and antiretroviral therapy (ART).

183 strategy in people with HIV (PWH) receiving antiretroviral therapy (ART).

184 ving with HIV-1 (PLWH) durably suppressed on antiretroviral therapy (ART).

185 preexposure prophylaxis (PrEP) or TFV-based antiretroviral therapy (ART).

186 ons with CD4 count <100 cells/muL initiating antiretroviral therapy (ART).

187 ell apoptosis in HIV-infected individuals on antiretroviral therapy (ART).

188 dentify key sites of viral persistence under antiretroviral therapy (ART).

189 ontributor to viral persistence in people on antiretroviral therapy (ART).

190 it is not always possible to initiate early antiretroviral therapy (ART).

191 chronic disease despite the effective use of antiretroviral therapy (ART).

192 (HIV-1) infection persists despite years of antiretroviral therapy (ART).

193 HIV-infected adults (18 to 40 years old) on antiretroviral therapy (ART).

194 drug-resistant HIV-1 jeopardizes success of antiretroviral therapy (ART).

195 y virus (HIV; PLWH) starting efavirenz-based antiretroviral therapy (ART).

196 paclitaxel (the control arm), together with antiretroviral therapy (ART; combined efavirenz, tenofov

197 who spontaneously control infection without antiretroviral therapy as well as preclinical immunizati

198 Despite antiretroviral therapy-associated improvement in CD4+ T-

199 ysis within a randomized trial, the Starting Antiretroviral Therapy at Three Points in Tuberculosis t

200 ion has dramatically decreased with maternal antiretroviral therapy, breast milk transmission account

201 ed by lifelong administration of combination antiretroviral therapy, but an effective vaccine will li

202 o are able to control HIV after cessation of antiretroviral therapy, but characteristics associated w

203 V) infection model, we show that combination antiretroviral therapy (c-ART) partially reverted microb

204 oor prognosis despite initiation of combined antiretroviral therapy (c-ART).

205 llular reservoirs despite effective combined antiretroviral therapy (cART) and there is viremia flare

206 d persistence during suppressive combination antiretroviral therapy (cART) and treatment interruption

207 The combined antiretroviral therapy (cART) can efficiently suppress H

208 Combination antiretroviral therapy (cART) failure is a major threat

209 dramatically since introduction of combined antiretroviral therapy (cART) in Switzerland.

210 also assessed after 8 months of combination antiretroviral therapy (cART) initiated in Fiebig II/III

211 rectly with the age of effective combination antiretroviral therapy (cART) initiation (P < .001, P =

212 tries to recommend initiation of combination antiretroviral therapy (cART) irrespective of CD4 cell c

213 transfer inhibitor (INSTI)-based combination antiretroviral therapy (cART) is associated with greater

214 suppressed patients on standard combination antiretroviral therapy (cART) switching to DTG + emtrici

215 ine if responses to standardized combination antiretroviral therapy (cART) were similar between group

216 ted individuals despite years of combination antiretroviral therapy (cART) with suppression of HIV-1

217 e setting of early initiation of combination antiretroviral therapy (cART), at high CD4 cell counts.

218 viremia initially controlled by combination antiretroviral therapy (cART), CPT31 monotherapy prevent

219 urce-limited settings (RLSs) for combination antiretroviral therapy (cART)-naive people living with H

220 nificant cognitive impairment in combination antiretroviral therapy (cART)-treated, perinatally human

221 HIV-monoinfected individuals on combination antiretroviral therapy (cART).

222 HIV infection (C-PHIV), despite combination antiretroviral therapy (cART).

223 Subjects were viremic on combination antiretroviral therapy (cART).

224 ab) in SIV-infected RM receiving combination antiretroviral therapy (cART).

225 h the potential to cause viral rebound after antiretroviral-therapy cessation in assessing the result

226 Even with antiretroviral therapy, children born to HIV-infected (H

227 Maternal receipt of 3-drug antiretroviral therapy compared with zidovudine was asso

228 sistently low CD4 counts despite efficacious antiretroviral therapy could have higher hospitalization

229 n in AIDS-related deaths achieved by current antiretroviral therapies, drawbacks including drug resis

230 To date, the impact of antiretroviral therapy duration on HIV-infected CD4(+) T

231 We included 7,255 patients starting antiretroviral therapy during 2004-2017, from 9 South Af

232 s or placebo in 26 individuals who initiated antiretroviral therapy during acute human immunodeficien

233 n 29 HIV-infected participants who initiated antiretroviral therapy during acute infection and underw

234 2 HIV-1-positive participants in the CNS HIV Antiretroviral Therapy Effects Research (CHARTER) study

235 Antiretroviral therapies efficiently block HIV-1 replica

236 ted adults who had been receiving continuous antiretroviral therapy for >=10 years and had undergone

237 Median duration of antiretroviral therapy for PLHIV was 8 years (interquart

238 Despite the use of antiretroviral therapy for the treatment of HIV-1 infect

239 Antiretroviral therapies greatly reduce the risk of HIV-

240 Though highly active antiretroviral therapy (HAART) has led to better long-te

241 While highly active antiretroviral therapy (HAART) is successful in controll

242 Despite increased access to highly active antiretroviral therapy (HAART), lung disease remains com

243 flammation, and the expansion of combination antiretroviral therapy has led to varied demographic and

244 Nonetheless, combination antiretroviral therapy has offered people with HIV the o

245 Antiretroviral therapy has revolutionized the treatment

246 Increased use of combination antiretroviral therapy has substantially reduced the ris

247 ment-experienced adults (>=18 years) failing antiretroviral therapy (HIV-1 RNA >=400 copies per mL) i

248 Despite effective antiretroviral therapy, HIV-1-infected cells continue to

249 xposures to human immunodeficiency (HIV) and antiretroviral therapy in utero may have adverse effects

250 ciated with development of TB-IRIS following antiretroviral therapy initiation.

251 sode of histoplasmosis within 6 months after antiretroviral therapy initiation.

252 histoplasmosis should be implemented before antiretroviral therapy initiation.

253 1 days (interquartile range 7-40 days) after antiretroviral therapy initiation.

254 HIV type 1 (HIV-1) and active TB commencing antiretroviral therapy, iNKT cells in TB-IRIS patients a

255 ntrast to individuals treated with long-term antiretroviral therapy, intact proviral sequences from e

256 ists in people living with HIV and receiving antiretroviral therapy is critical to develop cure strat

257 and pharmacodynamics in individuals naive to antiretroviral therapy is needed.

258 SIV-infected RMs.IMPORTANCE While effective, antiretroviral therapy is not a cure for HIV infection.

259 Antiretroviral therapy is recommended as soon as possibl

260 Combination antiretroviral therapy is the mainstay of HIV treatment,

261 nts diagnosed with HIV in the current era of antiretroviral therapy is unfortunately accompanied with

262 , we demonstrate that successful combination antiretroviral therapy (last HIV viral load <50 copies/m

263 HIV-1 persists in a latent form during antiretroviral therapy, mainly in CD4(+) T cells, thus h

264 76.5% males, 48.3% with cirrhosis, 98.3% on antiretroviral therapy, median CD4+ cell count 527 cells

265 ndomized, open-label study in HIV-1-infected antiretroviral therapy-naive adults (CD4+ >=50 cells/mm3

266 from participants infected with HIV who were antiretroviral therapy-naive during the observation peri

267 ith fat gain due to restoration to health in antiretroviral therapy-naive PLWH, which is compounded b

268 related action plans.Proportions adherent to antiretroviral therapy (proportion of days covered [PDC]

269 on or as an alternative for current HIV/AIDS antiretroviral therapy regimens.

270 Combination antiretroviral therapy results in metabolic abnormalitie

271 odeficiency virus (HIV) infection initiating antiretroviral therapy, screening serum for cryptococcal

272 Current antiretroviral therapy slows disease progression but doe

273 tance on virologic outcome during subsequent antiretroviral therapy still is unclear.IMPORTANCE The a

274 nced meaningful declines in lung function on antiretroviral therapy, suggesting a role for lung funct

275 Antiretroviral therapy suppresses but does not cure HIV-

276 HIV-infected individuals receiving long-term antiretroviral therapy; the secondary end point was to a

277 er the introduction of effective combination antiretroviral therapy, they became the most common AIDS

278 als Network (HPTN) 071 Population Effects of Antiretroviral Therapy to Reduce HIV Transmission (PopAR

279 ollowed by linkage to care and initiation of antiretroviral therapy to suppress viral replication.

280 enrolled in the Surveillance Monitoring for Antiretroviral Therapy Toxicities Study (SMARTT) cohort

281 A substantial proportion of antiretroviral therapy-treated PWH exhibited myocardial

282 There is no effect of combination antiretroviral therapy use on multiple myeloma or leukae

283 tments for age, body mass index, combination antiretroviral therapy use, CD4 cell counts, and HIV RNA

284 people who were HIV-positive did not report antiretroviral therapy use, of whom 2652 (68.4%) had vir

285 hy, acquired from the standard highly active antiretroviral therapy used to treat AIDS patients, like

286 d young adults (aged 10 to 24 years) failing antiretroviral therapy (viral load, >1,000 copies/ml on

287 he use of raltegravir- or dolutegravir-based antiretroviral therapy was associated with an adjusted o

288 -1 infection who had not previously received antiretroviral therapy were given 20 weeks of daily oral

289 Virally suppressed participants receiving antiretroviral therapy were randomized 1:1 for 12 weeks

290 nts with HIV infection receiving combination antiretroviral therapy were randomized equally to either

291 HIV was estimated to be from interruption to antiretroviral therapy, which could occur during a perio

292 To this end, HIV-1 patients on antiretroviral therapy who are reported to exhibit chron

293 our results allude to the supplementation of antiretroviral therapy with ALOX5 antagonists to rescue

294 cipants 40-75 years of age, receiving stable antiretroviral therapy with CD4+ T-cell count >100 cells

295 We compared safety and efficacy of antiretroviral therapy with either raltegravir or efavir

296 Some studies have associated antiretroviral therapy with increased risk of myocardial

297 vascular disease risk factors (eg, access to antiretroviral therapy with more benign cardiovascular d

298 man immunodeficiency virus (HIV) who were on antiretroviral therapy with suppressed HIV viremia and h

299 lly for individuals on long-term combination antiretroviral therapy with well controlled HIV.

300 years) infected with HIV-1 who were naive to antiretroviral therapy, with a plasma HIV-1 RNA concentr